التفاصيل البيبلوغرافية
| العنوان: |
Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer. |
| المؤلفون: |
Galland, Loïck, Lecuelle, Julie, Favier, Laure, Fraisse, Cléa, Lagrange, Aurélie, Kaderbhai, Courèche, Truntzer, Caroline, Ghiringhelli, François |
| المصدر: |
Cancers; Jun2021, Vol. 13 Issue 12, p3020, 1p |
| مصطلحات موضوعية: |
LUNG cancer prognosis, LUNG cancer, DRUG efficacy, STATISTICS, IMMUNE checkpoint inhibitors, SPECIALTY hospitals, MULTIVARIATE analysis, METASTASIS, RETROSPECTIVE studies, CANCER patients, CANCER treatment, PRE-tests & post-tests, NEUTROPHILS, SPLEEN diseases, DESCRIPTIVE statistics, SURVIVAL analysis (Biometry), LACTATE dehydrogenase, LEUKOCYTE count, SPLEEN, TUMOR markers, IMMUNOTHERAPY, PROPORTIONAL hazards models, THERAPEUTICS, EVALUATION |
| مصطلحات جغرافية: |
FRANCE |
| مستخلص: |
Simple Summary: Monoclonal antibodies targeting PD1/PD-L1 are game changers in the treatment of advanced non-small cell lung cancer (NSCLC), but biomarkers are lacking. We previously reported the prognostic role of splenic volume in digestive cancer and its correlation with the presence of immunosuppressive cells. The aim of this study was to evaluate the prognostic role of splenic volume in NSCLC patients treated with immune checkpoint inhibitors (ICIs). Monoclonal antibodies targeting PD1/PD-L1 are game changers in advanced non-small cell lung cancer (NSCLC), but biomarkers are lacking. We previously reported the prognostic role of splenic volume in digestive cancer and its correlation with the presence of immunosuppressive cells. The aim of this study was to evaluate the prognostic role of splenic volume in NSCLC patients treated with immune checkpoint inhibitors (ICIs). We conducted a retrospective study of 276 patients receiving ICIs for advanced NSCLC in the Georges François Leclerc Cancer Center. The association between splenic volume at baseline and at two months of therapy and progression-free survival (PFS) during ICI treatment or overall survival (OS) from ICI initiation was evaluated using univariate and multivariable Cox analyses. Splenic volume during treatment and the change in splenic volume were associated with poor PFS (respectively p = 0.02 and p = 0.001) and with OS (respectively p < 1.10−3 and p < 1.10−3). Baseline splenic volume at the first evaluation was also associated with poor OS (p = 0.001). LDH rate and dNLR were positively correlated with splenic volume, as well as with its evolution. After the adjustment of clinical variables, splenic volumes remained a predictive marker of immunotherapy efficacy. Splenic volume is a prognostic biomarker in patients with advanced NSCLC treated with ICIs. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder